MedDataX Logo

Coagulation Parameters During Pregnancy in Amniotic Fluid

NCT ID: NCT00458666

Last Updated: 2007-04-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

170 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Amniotic fluid embolism is a rare devastating thromboembolic event, which is probably caused by the entrance of amniotic fluid (AF) to the maternal circulation. While AF contains coagulation activators, their role during pregnancy has not been elucidated. The current study aimed to evaluate coagulation parameters in AF during human pregnancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Amniotic fluid embolism is a rare devastating thromboembolic event, which is probably caused by the entrance of amniotic fluid (AF) to the maternal circulation. While AF contains coagulation activators, their role during pregnancy has not been elucidated. The current study aimed to evaluate coagulation parameters in AF during human pregnancy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women undergoing amniocentesis during 15-35 weeks of gestation.

Exclusion Criteria

* A history of venous thromboembolism
* Systemic disease i.e.; diabetes, hypertension, hypo or hyper-thyroidism,
* Anticoagulant treatment
* Abnormal embryo
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rambam Health Care Campus

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Benjamin Brenner, M.D

Role: PRINCIPAL_INVESTIGATOR

Rambam Health Care Campus

Arie Drugan, M.D

Role: STUDY_CHAIR

Rambam Health Care Campus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept of Obstetrics and Gynecology, Rambam-Health Care Campus

Haifa, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Galit Sarig, Ph.D

Role: CONTACT

[email protected]
+972-50-2061462

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Arie Drugan, M.D

Role: primary

[email protected]
+972-50-206-2006

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CoagulationAmnioticFluid_CTIL

Identifier Type: -

Identifier Source: org_study_id